AORTHealthcare · Medical DevicesThe 9 Wall Street analysts covering Artivion, Inc. hold a median 12-month price target of $40 — +51.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 3 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Artivion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on AORT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +51.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2026 | Jefferies | Initiates | Buy | $31 |
| 18 Aug 2026 | Canaccord Genuity | Maintains | Buy | $39 → $40 |
| 18 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 20 July 2026 | Needham | Reiterates | Buy | — |
| 20 July 2026 | Needham | Reiterates | Buy | $44 |
| 16 June 2026 | Canaccord Genuity | Maintains | Buy | $36 |
| 16 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 8 May 2026 | Citizens | Maintains | Market Outperform | — |
| 8 May 2026 | Needham | Maintains | Buy | — |
| 10 Apr 2026 | Ladenburg Thalmann | Upgrade | Buy | — |
| 7 Apr 2026 | Needham | Reiterates | Buy | — |
| 13 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 2 Feb 2026 | Needham | Reiterates | Buy | — |
| 7 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 7 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 7 Nov 2025 | Needham | Maintains | Buy | — |
| 10 Oct 2025 | JMP Securities | Maintains | Market Outperform | — |
| 29 Sept 2025 | Canaccord Genuity | Maintains | Buy | — |
| 29 Sept 2025 | Stifel | Maintains | Buy | — |
| 22 Aug 2025 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AORT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Artivion, Inc. returned −42.2% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 7% of US stocks
Cheaper than 46% of US stocks
Cheaper than 34% of US stocks
Cheaper than 11% of US stocks
Higher than 56% of US stocks
Higher than 50% of US stocks
Higher than 77% of US stocks
Higher than 62% of US stocks
Higher than 29% of US stocks
Higher than 43% of US stocks
Higher than 62% of US stocks
Higher than 66% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Artivion, Inc. has a market value of $1.2B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $471.5M. The latest quarter grew 11.3% year on year.
Net income over the same four quarters: −$3.2M, a −0.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.07.
Free cash flow in the twelve months to 30 June 2026: −$9.2M, after $50.9M of capital spending.
Trailing P/E: 106.2×; forward P/E: 31.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.51%, paying out 0% of earnings.
Artivion, Inc. employs 1,800 people — $262K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Artivion, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Artivion announced that its management team will participate in two upcoming investor conferences. The excerpt specifically lists a presentation at the Stifel 2026 Healthcare Conference on November 10, 2026, at the Lotte New York Palace Hotel.
Why it matters — The announcement provides AORT watchers with details of an upcoming opportunity to hear from company management.
Artivion said it will release third-quarter 2026 financial results after the market closes on Thursday, November 5, 2026. The company will hold a teleconference call and live webcast that day at 4:30 p.m.
Why it matters — AORT watchers can note when the company plans to report results and provide a related call and webcast.
Artivion reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, driven by growth in stent grafts and On-X heart valves that offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while the adjusted EBITDA margin fell roughly 90 basis points to 21% amid higher R&D spending and costs related to the Endospan acquisition.
Why it matters — The results detail how segment growth is offsetting BioGlue declines and how higher spending related to R&D and the Endospan acquisition is affecting Artivion's margins.
Seeking Alpha published the transcript of Artivion, Inc.'s Q2 2026 earnings call, offering a detailed account of the company's quarterly results discussion. The excerpt provided contains only the transcript's headline identifying the call and its source.
Why it matters — A transcript of Artivion's Q2 2026 earnings call gives investors and analysts a complete record of management's commentary on the company's quarterly performance.
Artivion reported Q2 earnings of $0.13 per share, matching the Zacks Consensus Estimate. This compares to earnings of $0.24 per share in the same quarter a year ago.
Why it matters — AORT watchers would note whether the company's earnings continue to meet consensus expectations despite the year-over-year decline.
The 9 Wall Street analysts covering Artivion, Inc. have a median 12-month price target of $40, with estimates ranging from $31 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Artivion, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Artivion, Inc. 47 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Artivion, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +51.2% from the last close, and Ticker Nerd's factor model ranks Artivion, Inc. 47 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Artivion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AORT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $48 over the next 12 months.
Artivion, Inc. returned -42.2% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Artivion Inc. is a medical device company focused on cardiac and vascular surgery, with a particular emphasis on the treatment of aortic disease.
The most recent item we track (PRNewsWire, 28 Oct 2026): "Artivion to Participate in Upcoming Investor Conferences". Artivion announced that its management team will participate in two upcoming investor conferences. The excerpt specifically lists a presentation at the Stifel 2026 Healthcare Conference on November 10, 2026, at the Lotte New York Palace Hotel.
Artivion Inc. is a medical device company focused on cardiac and vascular surgery, with a particular emphasis on the treatment of aortic disease. Artivion develops, manufactures, processes, and distributes a broad portfolio of products used in complex surgical procedures, including aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable human tissues for cardiac and vascular applications. Its offerings support surgeons in open, hybrid, and minimally invasive procedures, making the company a specialized supplier in advanced cardiovascular care. Artivion also provides tissue preservation services, extending its role beyond devices into biologic solutions used in transplant and reconstructive settings. With products sold across global markets, Artivion occupies an important niche in the medical technology sector centered on aortic repair and cardiovascular surgery.
CEO Mr. James Patrick Mackin · 1,800 employees · United States · https://artivion.com
